

B. AMENDMENTS TO THE CLAIMS

1 - 29 Cancelled.

30. (Currently Amended). An antibody which elicits alloantigen specific hyporesponsiveness and which binds to the same epitope on human lymphocytes as the antibody produced by the cell line deposited as ATCC HB 11423.

31. (Previously presented). The antibody of Claim 30 wherein the antibody is a monoclonal antibody.

32. (Previously presented). The antibody of Claim 31 wherein the antibody is a rat antibody.

33. (Previously presented). The antibody of Claim 31 wherein the antibody is a humanized form of said antibody.

34. (Previously presented). The antibody of Claim 31 wherein the antibody is a chimeric form of said antibody.

35. (Currently Amended). A cell line which produces an antibody which elicits alloantigen specific hyporesponsiveness and which binds to the same epitope on human lymphocytes as the antibody produced by the cell line deposited as ATCC HB 11423.

36. (Previously presented). A process for producing an antibody comprising:  
producing an antibody by culturing the cell line of Claim 35.

Claim 37 has been cancelled without prejudice.

38. (Currently Amended). A composition, comprising:

(a) an antibody which elicits alloantigen specific hyporesponsiveness and which binds to the same epitope on human

lymphocytes as the antibody produced by the cell line deposited as ATCC HB 11423; and

(b) a pharmaceutically acceptable carrier, wherein said antibody is present in said composition in an amount effective to inhibit a T-cell mediated immune response.

39. (Previously presented). The composition of Claim 38 wherein the antibody is a monoclonal antibody.

40. (Previously presented). The composition of Claim 39 wherein the antibody is a rat antibody.

41. (Previously presented). The composition of Claim 39 wherein the antibody is a humanized form of said antibody.

42. (Previously presented). The antibody of Claim 39 wherein the antibody is a chimeric form of said antibody.

Claim 43 has been cancelled without prejudice.

44. (Previously presented). A composition, comprising:

(a) an antibody produced by the cell line deposited as ATCC HB11423; and

(b) a pharmaceutically acceptable carrier, wherein said antibody is present in said composition in an amount effective to inhibit a T-cell mediated immune response.